Behavioral Finance
May 23, 2026
In 2011, three behavioural economists at Harvard Business School and Duke University — Michael I. Norton, Daniel Mochon and Dan Ariely — conducted a series of […]
May 23, 2026
The Employee Benefit Expense line is the cleanest fixed-cost intensity metric on any Indian P&L. Here is how to read it, benchmark it, and use it — illustrated with Titan Biotech FY25's audited markers.
May 22, 2026
Iyengar & Lepper’s 2000 jam study and Sethi-Iyengar’s 2004 401(k) evidence show that wider option sets paralyse decision-makers. With ~1,500 MF schemes and 5,000+ listed stocks, Indian retail investors face an extreme choice-overload landscape. A four-step counter-measure checklist, and an educational case study on how Titan Biotech (BSE: 524717) FY25’s focused specialty-biotech portfolio reads as anti-choice-overload corporate behaviour.
May 22, 2026
The CEO-to-Median-Employee Pay Ratio mandated by Companies Act Section 197(12) read with Rule 5(1)(i) is one of the highest signal-to-noise governance disclosures in any Indian annual report. This educational piece decodes the metric, shows how to read its three-to-five-year arc, and illustrates the disciplined Pattern-A signature using Titan Biotech (BSE: 524717) FY25 audited markers — purely as a teaching case, not as a buy/sell view.
